PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28637984-6	2017	Although rosuvastatin reduced the levels of IL-1beta, they did not differ significantly between the PR and P groups.	Rosuvastatin Calcium	9-21	interleukin 1 beta	Rattus norvegicus	44-52	
25445360-10	2015	Additionally, the activation of astrocytes, the phosphorylation of extracellular signal-regulated kinase 42/44 (ERK(42/44)) and the expressions of TNFalpha and IL-1beta were inhibited significantly by rosuvastatin.	Rosuvastatin Calcium	201-213	interleukin 1 beta	Rattus norvegicus	160-168	
15681303-6	2005	In comparison with vehicle-treated SHRSP, rosuvastatin treatment attenuated the transcription of monocyte chemoattractant protein-1, transforming growth factor-beta1, IL-1beta, and tumor necrosis factor-alpha in the kidney, and of P-selectin in brain vessels and increased the transcription of endothelial nitric oxide synthase mRNA in the aorta.	Rosuvastatin Calcium	42-54	interleukin 1 beta	Rattus norvegicus	167-175	
29525080-6	2018	RESULTS: We found that combined rosuvastatin and resveratrol pretreatment not only significantly decreased the neurologic defective score, cerebral infarct volume, the levels of caspase-3, and Interleukin-1beta (IL-1beta) but also significantly increased the ratios of Bcl-2/Bax and LC3II/LC3I, as well as the level of Becline-1, compared with resveratrol alone or rosuvastatin alone pretreatment group.	Rosuvastatin Calcium	32-44	interleukin 1 beta	Rattus norvegicus	193-210	
29525080-6	2018	RESULTS: We found that combined rosuvastatin and resveratrol pretreatment not only significantly decreased the neurologic defective score, cerebral infarct volume, the levels of caspase-3, and Interleukin-1beta (IL-1beta) but also significantly increased the ratios of Bcl-2/Bax and LC3II/LC3I, as well as the level of Becline-1, compared with resveratrol alone or rosuvastatin alone pretreatment group.	Rosuvastatin Calcium	32-44	interleukin 1 beta	Rattus norvegicus	212-220	
19948880-12	2010	The messenger RNA expression of TNF-alpha, IL-1beta, IFN-gamma, MCP1, ICAM-1 and ET-1 was increased in DSH, which was attenuated by rosuvastatin treatment.	Rosuvastatin Calcium	132-144	interleukin 1 beta	Rattus norvegicus	43-51	
27338064-13	2016	Rosuvastatin treatment reduced the infiltration of inflammatory cells and TNF-alpha and IL-1beta expression.	Rosuvastatin Calcium	0-12	interleukin 1 beta	Rattus norvegicus	88-96	
26633263-7	2016	Moreover, rosuvastatin markedly inhibited microglial activation in LPS-challenged cells by affecting both their morphology and functions as it inhibited LPS-elicited phagocytosis and inhibited pro-inflammatory cytokine (IL-1beta, TNF-alpha) production, concomitantly increasing the level of IL-10, an anti-inflammatory cytokine.	Rosuvastatin Calcium	10-22	interleukin 1 beta	Rattus norvegicus	220-228